Healthline Aerosol Medicine provides this list of
references on the above named topic as a convenience to respiratory
therapists, pulmonologists and medical aerosol scientists. You
may view or print the list or use "cut/copy/paste"
commands to insert into documents. Great for students and
researchers! Disclaimer: Please note that this list is not
guaranteed to be either exhaustive or completely up-to-date.
We encourage anyone who would like to update this list, or share their special list of
references on any legitimate aerosol medicine, respiratory therapy
or related subject to forward it to Healthline Aerosol Medicine by e-mail
for posting at this web site.
Ipratropium
Bromide
Campbell S. For COPD a combination of ipratropium bromide
and albuterol sulfate is more effective than albuterol base. Arch
Intern Med. 1999;159:156-60.
Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic
evaluation of a combination of ipratropium plus albuterol
compared with ipratropium alone and albuterol alone in COPD. Chest.
1999;115:635-41.
Zorc JJ, Pusic MV, Ogborn CJ, et al. Ipratropium bromide
added to asthma treatment in the pediatric emergency
department. Pediatrics. 1999;103:748-52.
Brophy C, Ahmed B, Bayston S, et al. How long should
Atrovent be given in acute asthma? Thorax.
1998;53:363-7.
Calvo GM, Calvo AM, Marin HF, Moya GJ. Is it useful to add
an anticholinergic treatment to beta 2-adrenergic medication
in acute asthma attack? J Investig Allergol Clin Immunol.
1998;8:30-4.
Ducharme FM, Davis GM. Randomized controlled trial of
ipratropium bromide and frequent low doses of salbutamol in
the management of mild and moderate acute pediatric asthma. J
Pediatr. 1998;133:479-85.
Fein ED, Grimm DR, Lesser M, et al. The effects of
ipratropium bromide on histamine-induced bronchoconstriction
in subjects with cervical spinal cord injury. J Asthma.
1998;35:49-55.
Gross N, Tashkin D, Miller R, et al. Inhalation by
nebulization of albuterol-ipratropium combination (Dey
combination) is superior to either agent alone in the
treatment of chronic obstructive pulmonary disease. Respiration.
1998;65:354-62.
Kaiser HB, Findlay SR, Georgitis JW, et al. The
anticholinergic agent, ipratropium bromide, is useful in the
treatment of rhinorrhea associated with perennial allergic
rhinitis. Allergy Asthma Proc. 1998;19:23-9.
Lanes SF, Garrett JE, Wentworth CE 3rd. The effect of
adding ipratropium bromide to salbutamol in the treatment of
acute asthma: a pooled analysis of three trials. Chest.
1998;114:365-72.
Lin RY, Pesola GR, Bakalchuk L, et al. Superiority of
ipratropium plus albuterol over albuterol alone in the
emergency department management of adult asthma: a randomized
clinical trial. Ann Emerg Med. 1998;31:208-13.
Pillet O, Manier G, Castaing Y. Anticholinergic versus beta
2-agonist on gas exchange in COPD: a comparative study in 15
patients. Monaldi Arch Chest Dis. 1998;53:3-8.
Qureshi F, Pestian J, Davis P, Zaritsky A. Effect of
nebulized ipratropium on the hospitalization rates of children
with asthma. N Engl J Med. 1998;339:1030-5.
Tsukino M, Nishimura K, Ikeda A, et al. Effects of
theophylline and ipratropium bromide on exercise performance
in patients with stable chronic obstructive pulmonary disease.
Thorax. 1998;53:269-73.
Becker B, Borum S, Nielsen K, et al. A time-dose study of
the effect of topical ipratropium bromide on methacholine-induced
rhinorrhoea in patients with perennial non- allergic rhinitis.
Clin Otolaryngol. 1997;22:132-4.
Bollert FG, Matusiewicz SP, Dewar MH, et al. Comparative
efficacy and potency of ipratropium via Turbuhaler and
pressurized metered-dose inhaler in reversible airflow
obstruction. Eur Respir J. 1997;10:1824-8.
Burki NK. The effects of the combination of inhaled
ipratropium and oral theophylline in asthma. Chest.
1997;111:1509-13.
COMBIVENT Inhalation Solution Study Group. Routine
nebulized ipratropium and albuterol together are better than
either alone in COPD . Chest. 1997;112:1514-21.
Dagnone AJ, Parlow JL. Effects of inhaled albuterol and
ipratropium bromide on autonomic control of the cardiovascular
system. Chest. 1997;111:1514-8.
FitzGerald JM, Grunfeld A, Pare PD, et al. The clinical
efficacy of combination nebulized anticholinergic and
adrenergic bronchodilators vs nebulized adrenergic
bronchodilator alone in acute asthma. Canadian Combivent Study
Group. Chest. 1997;111:311-5.
Friedman M. Combined bronchodilator therapy in the
management of chronic obstructive pulmonary disease. Respirology.
1997;2 Suppl 1:S19-23.
Garrett JE, Town GI, Rodwell P, Kelly AM. Nebulized
salbutamol with and without ipratropium bromide in the
treatment of acute asthma. J Allergy Clin Immunol.
1997;100:165-70.
Garrett JE. Combined anticholinergic therapy in the
management of acute asthma. Respirology. 1997;2 Suppl
1:S17-8.
Konradova V, Uhlik J, Vajner L, Zocova J. Effect of an
adrenergic agonist and a cholinergic antagonist on the airway
epithelium. Vet Med (Praha). 1997;42:289-93.
McFadden ER Jr, elSanadi N, Strauss L, et al. The influence
of parasympatholytics on the resolution of acute attacks of
asthma. Am J Med. 1997;102:7-13.
Meltzer EO, Orgel HA, Biondi R, et al. Ipratropium nasal
spray in children with perennial rhinitis. Ann Allergy
Asthma Immunol. 1997;78:485-91.
Naspitz CK. Long acting inhaled beta 2 agonists and inhaled
anticholinergic drugs: benefits and side effects in childhood
asthma. Pediatr Pulmonol Suppl. 1997;16:96-7.
Ostberg B, Winther B, Borum P, Mygind N. Common cold and
high-dose ipratropium bromide: use of anticholinergic
medication as an indicator of reflex-mediated hypersecretion. Rhinology.
1997;35:58-62.
Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized
ipratropium in severely asthmatic children. Ann Emerg Med.
1997;29:205-11.
Ryan CA. Ipratropium bromide induced unilateral mydriasis
[letter]. Ir Med J. 1997;90:76.
Sammartino LP, Lines D. Efficacy of ipratropium bromide by
metered dose aerosol and aerochamber in acute paediatric
bronchiolitis [letter]. J Paediatr Child Health.
1997;33:459.
Shivaram U, Cash ME, Mateo F, Shim C. Effects of high-dose
ipratropium bromide and oral aminophylline on spirometry and
exercise tolerance in COPD. Respir Med. 1997;91:327-34.
Borum S, Becker B, Mygind N, Borum P. Comparison between
the effect of ipratropium bromide as a pressurized aerosol and
as an aqueous pump spray on methacholine-induced rhinorrhoea. Rhinology.
1996;34:198-200.
Friedman M. A multicenter study of nebulized bronchodilator
solutions in chronic obstructive pulmonary disease. Am J
Med. 1996;100:30S-39S.
Groeben H, Brown RH. Ipratropium decreases airway size in
dogs by preferential M2 muscarinic receptor blockade in vivo. Anesthesiology.
1996;85:867-73.
Hayden FG, Diamond L, Wood PB, et al. Effectiveness and
safety of intranasal ipratropium bromide in common colds. A
randomized, double-blind, placebo-controlled trial. Ann
Intern Med. 1996;125:89-97.
Ikeda A, Nishimura K, Koyama H, et al. Dose response study
of ipratropium bromide aerosol on maximum exercise performance
in stable patients with chronic obstructive pulmonary disease.
Thorax. 1996;51:48-53.
Ikeda A, Nishimura K, Izumi T. Bronchodilating effects of
combined therapy with clinical dosages of ipratropium bromide
and salbutamol for stable COPD [letter]. Chest.
1996;109:294.
Ingram RH Jr. Bronchodilating effects of combined therapy
with clinical dosages of ipratropium bromide and salbutamol
for stable COPD [letter; comment]. Chest. 1996;109:293.
Karpel JP, Schacter EN, Fanta C, et al. A comparison of
ipratropium and albuterol vs albuterol alone for the treatment
of acute asthma. Chest. 1996;110:611-6.
Pfister SM. Ipratropium bromide (Atrovent) nasal spray. A
new treatment for rhinorrhea [news]. Nurse Pract.
1996;21:104, 107-8.
Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy
with ipratropium is associated with improved lung function in
patients with COPD. A retrospective analysis of data from
seven clinical trials. Chest. 1996;110:62-70.
Rubin BK, Albers GM. Use of anticholinergic bronchodilation
in children. Am J Med. 1996;100:49S-53S.
Teramoto S, Fukuchi Y, Ouchi Y. A week-long course of
inhaled beta-agonist or anticholinergic agent may reduce
dyspnea during exercise in COPD [letter; comment]. Chest.
1996;109:1666-7.
Wilding PJ, Clark MM, Pavord ID, et al. Effect of cessation
of short-term therapy with ipratropium bromide on lung
function and airway responsiveness. Eur Respir J.
1996;9:1627-31.
Zanen P, Go LT, Lammers JW. Optimal particle size for beta
2 agonist and anticholinergic aerosols in patients with severe
airflow obstruction. Thorax. 1996;51:977-80.
Ashutosh K, Dev G, Steele D. Nonbronchodilator effects of
pirbuterol and ipratropium in chronic obstructive pulmonary
disease. Chest. 1995;107:173-8.
Blosser SA, Maxwell SL, Reeves-Hoche MK, et al. Is an
anticholinergic agent superior to a beta 2-agonist in
improving dyspnea and exercise limitation in COPD? Chest.
1995;108:730-5.
Geiger-Bronsky MJ. Anticholinergic therapy in the
critically ill patient with bronchospasm. AACN Clin Issues.
1995;6:287-96.
Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating
effects of combined therapy with clinical dosages of
ipratropium bromide and salbutamol for stable COPD: comparison
with ipratropium bromide alone. Chest. 1995;107:401-5.
Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of
the bronchodilating effects of salmeterol, salbutamol and
ipratropium bromide in patients with chronic obstructive
pulmonary disease. Pulm Pharmacol. 1995;8:267-71.
Moayyedi P, Congleton J, Page RL, et al. Comparison of
nebulised salbutamol and ipratropium bromide with salbutamol
alone in the treatment of chronic obstructive pulmonary
disease. Thorax. 1995;50:834-7.
Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K,
Izumi T. The additive effect of theophylline on a high-dose
combination of inhaled salbutamol and ipratropium bromide in
stable COPD. Chest. 1995;107:718-23.
Osmond MH, Klassen TP. Use of ipratropium for severe asthma
[letter; comment]. J Pediatr. 1995;127:842.
Schuh S, Johnson DW, Callahan S, et al. Efficacy of
frequent nebulized ipratropium bromide added to frequent
high-dose albuterol therapy in severe childhood asthma. J
Pediatr. 1995;126:639-45.
Zielinski J. Effects of ipratropium bromide on pulmonary
hemodynamics in COPD [letter; comment]. Chest.
1995;108:1181-2.
Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A
comparison of inhaled ipratropium, oral theophylline plus
inhaled beta-agonist, and the combination of all three in
patients with COPD. Chest. 1994;105:1089-94.
Yang SC, Yang SP, Lee TS. Nebulized ipratropium bromide in
ventilator-assisted patients with chronic bronchitis. Chest.
1994;105:1511-5.
Jubran A, Gross N, Ramsdell J, et al. Comparative
cost-effectiveness analysis of theophylline and ipratropium
bromide in chronic obstructive pulmonary disease. A three-
center study. Chest. 1993;103:678-84.
Sanchez I, De Koster J, Holbrow J, Chernick V. The effect
of high doses of inhaled salbutamol and ipratropium bromide in
patients with stable cystic fibrosis. Chest.
1993;104:842-6.
Freeman W, Javaid A, Cayton RM. The effect of ipratropium
bromide on maximal exercise capacity in asthmatic and
non-asthmatic men. Respir Med. 1992;86:151-5.
Schuh S, Johnson D, Canny G, et al. Efficacy of adding
nebulized ipratropium bromide to nebulized albuterol therapy
in acute bronchiolitis. Pediatrics. 1992;90:920-3.
Teale C, Morrison JF, Muers MF, Pearson SB. Response to
nebulized ipratropium bromide and terbutaline in acute severe
asthma. Respir Med. 1992;86:215-8.
Shrestha M, O'Brien T, Haddox R, Gourlay HS, Reed G.
Decreased duration of emergency department treatment of
chronic obstructive pulmonary disease exacerbations with the
addition of ipratropium bromide to beta-agonist therapy. Ann
Emerg Med. 1991;20:1206-9.
Whyte KF, Gould GA, Jeffrey AA, et al. Dose of nebulized
ipratropium bromide in acute severe asthma. Respir Med.
1991;85:517-20.
Barros MJ, Rees PJ. Bronchodilator responses to salbutamol
followed by ipratropium bromide in partially reversible
airflow obstruction. Respir Med. 1990;84:371-5.
Brundage KL, Mohsini KG, Froese AB, Fisher JT.
Bronchodilator response to ipratropium bromide in infants with
bronchopulmonary dysplasia. Am Rev Respir Dis.
1990;142:1137-42.
Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of
the effects of ipratropium bromide and metaproterenol sulfate
in acute exacerbations of COPD. Chest. 1990;98:835-9.
Lynn MM, Holdcroft C. Ipratropium: an alternative for
bronchodilator therapy. Nurse Pract. 1990;15:44-8.
Phanichyakarn P, Kraisarin C, Sasisakulporn C. Comparison
of inhaled terbutaline and inhaled terbutaline plus
ipratropium bromide in acute asthmatic children. Asian Pac
J Allergy Immunol. 1990;8:45-8.
Wesseling G, Vonk HM, Wouters EF. Effects of inhalation of
beta 2-sympathomimetic and anticholinergic agents on the
impedance of the respiratory system in normal subjects. Chest.
1990;97:1137-40.
Gross NJ, Petty TL, Friedman M, et al. Dose response to
ipratropium as a nebulized solution in patients with chronic
obstructive pulmonary disease. A three-center study. Am Rev
Respir Dis. 1989;139:1188-91.
Henry RL, Hankin RG, Abramson R. Comparison of
preservative-free and preservative-containing ipratropium
bromide. Aust Paediatr J. 1989;25:86-8.
Johnson MA, Newman SP, Bloom R, et al. Delivery of
albuterol and ipratropium bromide from two nebulizer systems
in chronic stable asthma. Efficacy and pulmonary deposition. Chest.
1989;96:6-10.
LeDoux EJ, Morris JF, Temple WP, Duncan C. Standard and
double dose ipratropium bromide and combined ipratropium
bromide and inhaled metaproterenol in COPD. Chest.
1989;95:1013-6.
Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators
ipratropium bromide and metaproterenol in adults with CF. Chest.
1989;95:861-4.
Atsmon J. Ipratropium bromide in COPD and asthma. Am J
Med Sci. 1988;296:140-2.
Gross NJ. Ipratropium bromide. N Engl J Med.
1988;319:486-94.
Mann KV, Leon AL, Tietze KJ. Use of ipratropium bromide in
obstructive lung disease. Clin Pharm. 1988;7:670-80.
Milner AD. Ipratropium bromide and airways obstruction in
childhood. Postgrad Med J. 1987;63 Suppl 1:53-6.
Anderson WM. Hemodynamic and non-bronchial effects of
ipratropium bromide. Am J Med. 1986;81:45-53.
Chervinsky P. Concomitant bronchodilator therapy and
ipratropium bromide. A clinical review. Am J Med.
1986;81:67-73.
Cugell DW. Clinical pharmacology and toxicology of
ipratropium bromide. Am J Med. 1986;81:18-22.
Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison
of the bronchodilating effects of a beta-2 adrenergic agent
(albuterol) and an anticholinergic agent (ipratropium
bromide), given by aerosol alone or in sequence. N Engl J
Med. 1986;315:735-9.
Farrow PR, Fancourt GJ. Does ipratropium bromide by
nebulizer and face-mask have local ocular effects? Hum
Toxicol. 1986;5:53-4.
Gunawardena KA, Smith AP, Shankleman J. A comparison of
metered dose inhalers with nebulizers from the delivery of
ipratropium bromide in domiciliary practice. Br J Dis
Chest. 1986;80:170-8.
Lakshminarayan S. Ipratropium bromide in chronic
bronchitis/emphysema. A review of the literature. Am J Med.
1986;81:76-80.
Morris HG. Review of ipratropium bromide in induced
bronchospasm in patients with asthma. Am J Med.
1986;81:36-44.
Poppius H, Sovijarvi AR, Tammilehto L. Lack of protective
effect of high-dose ipratropium on bronchoconstriction
following exercise with cold air breathing in patients with
mild asthma. Eur J Respir Dis. 1986;68:319-25.
Schlueter DP. Ipratropium bromide in asthma. A review of
the literature. Am J Med. 1986;81:55-60.
Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of
the anticholinergic bronchodilator ipratropium bromide with
metaproterenol in chronic obstructive pulmonary disease. A 90-
day multi-center study. Am J Med. 1986;81:81-90.
Taylor RG, Pavia D, Agnew JE, et al. Effect of four weeks'
high dose ipratropium bromide treatment on lung mucociliary
clearance. Thorax. 1986;41:295-300.
Wanner A. Effect of ipratropium bromide on airway
mucociliary function. Am J Med. 1986;81:23-7.
Massey KL, Gotz VP. Ipratropium bromide. Drug Intell
Clin Pharm. 1985;19:5-12.
Ashutosh K, Lang H. Comparison between long-term treatment
of chronic bronchitic airway obstruction with ipratropium
bromide and metaproterenol. Ann Allergy. 1984;53:401-6.
Peel ET, Anderson G, Cheong B, Broderick N. A comparison of
oxitropium bromide and ipratropium bromide in asthma. Eur J
Respir Dis. 1984;65:106-8.
Tobin MJ, Hughes JA, Hutchison DC. Effects of ipratropium
bromide and fenoterol aerosols on exercise tolerance. Eur J
Respir Dis. 1984;65:441-6.
Bruderman I, Cohen Aronovski R, Smorzik J. A comparative
study of various combinations of ipratropium bromide and
metaproterenol in allergic asthmatic patients. Chest.
1983;83:208-10.
Hughes JA, Tobin MJ, Bellamy D, Hutchison DC. Effects of
ipratropium bromide and fenoterol aerosols in pulmonary
emphysema. Thorax. 1982;37:667-70.
Shenfield GM. Combination bronchodilator therapy. Drugs.
1982;24:414-39.
Lulling J, Delwiche JP, Prignot J. Early bronchodilating
effect of oxitropium bromide in comparison with ipratropium
bromide. Respiration. 1981;42:188-92.
Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS.
Ipratropium bromide: a review of its pharmacological
properties and therapeutic efficacy in asthma and chronic
bronchitis. Drugs. 1980;20:237-66.
Engelhardt A. Pharmacology and toxicology of Atrovent. Scand
J Respir Dis Suppl. 1979;103:110-5.
Simonsson BG. Acute effects of ipratropium bromide (ITBR,
Sch 1000, Atrovent): a review of previous studies. Scand J
Respir Dis Suppl. 1979;103:130-42.
Vlagopoulos T, Townley RG, Ghazanshahi S, et al. Comparison
of the bronchodilating effects of SCH 1000 with isoproterenol
in patients with bronchial asthma. Ann Allergy.
1976;36:223-30.
Compiled 7/30/99. Based on MedLine
Update through June, 1999. A
Scanlan Bibliography
Company
| Contacts | Products
| Sales
|
